Biogen Inc. is a global biotechnology company dedicated to discovering, developing, and delivering innovative therapies for neurological diseases. Its mission focuses on addressing the unmet needs of patients with conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. Biogen's strategy emphasizes cutting-edge research, collaboration with academic institutions, and leveraging advanced technologies to enhance drug development. The company operates through a robust pipeline of therapies and a commitment to patient-centric solutions, aiming to improve the quality of life for individuals affected by debilitating neurological disorders.

BIOGEN INC

Biogen's stock has faced significant pressure, dropping over 6% following its disappointing forecast for 2025 adjusted earnings per share (EPS). The company anticipates an EPS range of $15.25 to $16.25, which falls short of the consensus estimate of $16.16. This negative outlook is compounded by a backdrop of mixed corporate...

Biogen's Stock Plummets Over 6% as 2025 Earnings Forecast Falls Short of Expectations

Biogen's stock has taken a hit, dropping over 6% after a disappointing 2025 earnings forecast that missed expectations. With a challenging landscape for MS treatments and a cautious market outlook, can Biogen's new strategies and partnerships turn the tide?